Zobrazeno 1 - 10
of 197
pro vyhledávání: '"Natalia, Buza"'
Autor:
Dana M. Roque, Eric R. Siegel, Natalia Buza, Stefania Bellone, Gloria S. Huang, Gary Altwerger, Vaagn Andikyan, Mitchell Clark, Masoud Azodi, Peter E. Schwartz, Gautam G. Rao, Elena Ratner, Alessandro D. Santin
Publikováno v:
BJC Reports, Vol 2, Iss 1, Pp 1-7 (2024)
Abstract Background Ixabepilone may retain activity in paclitaxel-resistant disease. We previously reported improved response rates (ORR), progression-free (PFS), and overall survival (OS) conferred by ixabepilone+bevacizumab (IXA + BEV) compared to
Externí odkaz:
https://doaj.org/article/f49671ab396045a1849b78083c690bd0
Publikováno v:
Gynecologic Oncology Reports, Vol 56, Iss , Pp 101524- (2024)
Background: Synchronous endometrial and ovarian carcinomas represent up to 10% of all endometrial and ovarian tumors. These are diagnostically challenging cases to determine if they represent dual primary tumors or related metastatic tumors. Case: A
Externí odkaz:
https://doaj.org/article/2ddaaff38f66436889db9cfdb27b4f0b
Autor:
Jessie Y. Li, Levent Mutlu, Joan Tymon-Rosario, Wafa Khadraoui, Nupur Nagarkatti, Pei Hui, Natalia Buza, Lingeng Lu, Peter Schwartz, Gulden Menderes
Publikováno v:
Gynecologic Oncology Reports, Vol 39, Iss , Pp 100913- (2022)
Objective: To examine clinicopathologic characteristics and oncologic outcomes of patients diagnosed with Mullerian adenosarcoma and to evaluate ovarian preservation as a practical management option in early-stage disease. Methods: A retrospective re
Externí odkaz:
https://doaj.org/article/493efdc23a7f4653ad2ee708eb39fcde
Autor:
Emanuele Perrone, Paola Manara, Salvatore Lopez, Stefania Bellone, Elena Bonazzoli, Aranzazu Manzano, Luca Zammataro, Anna Bianchi, Burak Zeybek, Natalia Buza, Joan Tymon‐Rosario, Gary Altwerger, Chanhee Han, Gulden Menderes, Gloria S. Huang, Elena Ratner, Dan‐Arin Silasi, Masoud Azodi, Pei Hui, Peter E. Schwartz, Giovanni Scambia, Alessandro D. Santin
Publikováno v:
Molecular Oncology, Vol 14, Iss 3, Pp 645-656 (2020)
Endometrial cancer is the most common gynecologic malignancy in developed countries. The antibody–drug conjugate (ADC) sacituzumab govitecan (SG) targets trophoblast cell‐surface antigen‐2 (Trop‐2) – a cell‐surface glycoprotein highly exp
Externí odkaz:
https://doaj.org/article/4855a08bc9b94673965f1e87191a9728
Autor:
Blair McNamara, Justin Harold, Diego Manavella, Stefania Bellone, Levent Mutlu, Tobias Max Philipp Hartwich, Margherita Zipponi, Yang Yang-Hartwich, Cem Demirkiran, Miguel Skyler Z. Verzosa, Kevin Yang, Jungmin Choi, Weilai Dong, Natalia Buza, Pei Hui, Gary Altwerger, Gloria S. Huang, Vaagn Andikyan, Mitchell Clark, Elena Ratner, Masoud Azodi, Peter E. Schwartz, Elizabeth A. Burton, Hiroaki Inagaki, Aaron Albers, Chao Zhang, Gideon Bollag, Joseph Schlessinger, Alessandro D. Santin
Publikováno v:
Gynecologic Oncology. 172:65-71
Autor:
Dennis, Mauricio, Stefania, Bellone, Levent, Mutlu, Blair, McNamara, Diego D, Manavella, Cem, Demirkiran, Miguel Skyler Z, Verzosa, Natalia, Buza, Pei, Hui, Tobias Max Philipp, Hartwich, Justin, Harold, Yang, Yang-Hartwich, Margherita, Zipponi, Gary, Altwerger, Elena, Ratner, Gloria S, Huang, Mitchell, Clark, Vaagn, Andikyan, Masoud, Azodi, Peter E, Schwartz, Alessandro D, Santin
Publikováno v:
Gynecologic Oncology. 170:38-45
Carcinosarcomas are highly aggressive gynecologic malignancies containing both carcinomatous and sarcomatous elements with heterogeneous HER2/neu expression and limited therapeutic options. We compared the efficacy of trastuzumab deruxtecan (DS-8201a
Publikováno v:
Pathology. 55:8-18
Human epidermal growth factor receptor 2 (HER2) is a prognostic biomarker and therapeutic target in carcinomas of the breast, stomach and colon. In 2018, clinical trial data confirmed the prognostic and predictive role of HER2 in uterine serous carci
Autor:
Xavier Matias-Guiu, Christina I. Selinger, Lyndal Anderson, Natalia Buza, Lora H. Ellenson, Oluwole Fadare, Raji Ganesan, Philip P.C. Ip, Jose Palacios, Carlos Parra-Herran, Maria R. Raspollini, Robert A. Soslow, Henrica M.J. Werner, Sigurd F. Lax, W. Glenn McCluggage
Publikováno v:
International Journal of Gynecological Pathology. 41:S90-S118
Endometrial cancer is one of the most common cancers among women. The International Collaboration on Cancer Reporting (ICCR) developed a standardized endometrial cancer data set in 2011, which provided detailed recommendations for the reporting of re
Autor:
Silvia Pelligra, Natalia Buza, Pei Hui, Stefania Bellone, Burak Zeybek, Elena Ratner, Peter E. Schwartz, Giovanni Scambia, Alessandro D. Santin
Publikováno v:
Gynecologic Oncology Reports, Vol 32, Iss , Pp - (2020)
Background: Uterine serous carcinoma (USC) is an aggressive variant of endometrial cancer overexpressing HER2/neu in about 30% of cases. Trastuzumab, a humanized monoclonal antibody targeting Her2/Neu, in combination with carboplatin/paclitaxel, is c
Externí odkaz:
https://doaj.org/article/ff2bcf379200416db1549409a4ed7de8
Autor:
Emanuele Perrone, Salvatore Lopez, Burak Zeybek, Stefania Bellone, Elena Bonazzoli, Silvia Pelligra, Luca Zammataro, Aranzazu Manzano, Paola Manara, Anna Bianchi, Natalia Buza, Joan Tymon-Rosario, Gary Altwerger, Chanhee Han, Gulden Menderes, Elena Ratner, Dan-Arin Silasi, Masoud Azodi, Pei Hui, Peter E. Schwartz, Giovanni Scambia, Alessandro D. Santin
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Background: Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. Sacituzumab govitecan (SG) is a novel antibody-drug-conjugate (ADC) targeting trophoblast-antigen-2 (Trop-2), a cell surface glycoprotein highly expressed in many
Externí odkaz:
https://doaj.org/article/2f3ecf6859594b69a06c011b962dbb6a